AD Pipeline Watch: Rezpegaldesleukin Hits Primary and Key Secondary Endpoints in REZOLVE-AD Phase 2b Study
Rezpegaldesleukin met primary and key secondary endpoints at Week 16 in patients with moderate-to-severe atopic dermatitis (AD), according to the REZOLVE-AD Phase 2b study, which was presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.